Search Results

aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company) today announced that its partner Kyorin Pharmaceutical Co., Ltd. (Kyorin), a wholly owned subsidiary of Kyorin Holdings, Inc., has dosed the first patient in Japan in EFZO-FIT™, a global pivotal Phase 3 study to evaluate the efficacy and safety of the Company’s lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease (ILD).

Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.

Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.

Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014.

AriBio Co., Ltd. announces the expansion of testing for Alzheimer’s disease by entering into a strategic collaboration with Kentucky Clinical Trial Laboratory for the testing of cerebral spinal fluid to accurately and efficiently aid in the diagnosis of Alzheimer’s disease using the Lumipulse® system from FujireBio.

NRx Pharmaceuticals, Inc. today announced that its Asia Pacific strategic partner Lotus Pharmaceutical Co. Ltd (1975.TW) identified enrollment completion of the NRx clinical trial in bipolar depression as a material event in is February 7 financial filing.